Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer

1 month ago 5
Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses successful pretreated patients with RAS-mutant non-small compartment lung crab (NSCLC) successful a signifier 1/2 proceedings led by The University of Texas MD Anderson Cancer Center.
Read Entire Article